Treatment-Related Immune Dysfunction and Infection Risk in Cancer

Abstract

Treatment-related immune dysfunction is a significant and well-documented contributor to increased infection risk among cancer patients. As advances in oncologic therapies have extended survival, clinicians are increasingly challenged by immunosuppression arising from both traditional cytotoxic regimens and newer molecularly targeted or immunomodulatory agents. This review synthesizes current evidence on the epidemiology, mechanisms, and clinical features of immune dysfunction in cancer therapy, discusses diagnostic and management strategies, highlights recent therapeutic advances, and summarizes contemporary guideline recommendations to optimize infection prevention and outcomes in this vulnerable population.

Introduction

Cancer patients, by virtue of both malignancy and its treatment, face heightened susceptibility to infections due to complex immune impairment. The advent of immunotherapies and targeted agents, alongside established modalities like chemotherapy and hematopoietic stem cell transplantation (HSCT), has transformed the landscape of cancer care but also introduced novel patterns of immunosuppression. Infections remain a leading cause of morbidity and mortality in this population, underscoring the need for clinicians to recognize, anticipate, and mitigate treatment-related immune dysfunction. This article comprehensively reviews the current understanding of immune compromise associated with cancer therapy, focusing on clinical implications and evidence-based management strategies for infection risk.

Epidemiology / Disease Burden

The burden of infection in cancer patients is substantial, with sepsis and pneumonia among the most common causes of non-cancer death. Studies report infection rates ranging from 10% to over 50% depending on cancer type, treatment modality, and immune status. Hematological malignancies, especially acute leukemias and lymphomas, carry the highest risk, particularly during periods of neutropenia. Solid tumor patients, while generally at lower risk, are not exempt, especially with aggressive chemotherapy or combination regimens. The rise of immunotherapies has also been associated with unique infection patterns, including opportunistic infections and reactivation of latent pathogens. Globally, infection-related mortality in cancer patients remains significant, highlighting the critical need for vigilant assessment and preventive strategies in oncologic care.

Pathophysiology

Immune dysfunction in cancer therapy arises from multiple, often overlapping mechanisms. Cytotoxic chemotherapies induce neutropenia, profoundly diminishing innate immune defenses. HSCT and certain monoclonal antibodies (e.g., rituximab, alemtuzumab) cause prolonged lymphocyte depletion, impairing adaptive immunity. Corticosteroids and other immunosuppressants reduce macrophage and T-cell function. Targeted therapies (e.g., BTK inhibitors, PI3K inhibitors) can disrupt key signaling pathways in lymphocyte and neutrophil biology, further compounding risk. Immune checkpoint inhibitors, while restoring antitumor immunity, may paradoxically precipitate immune-related adverse events requiring immunosuppression, thus increasing infection susceptibility. Disruption of mucosal barriers, central venous catheters, and compromised nutritional status further contribute to infection risk in the cancer population.

Risk Factors

Risk factors for treatment-related infection span host, disease, and treatment domains. Host-related factors include advanced age, comorbidities (e.g., diabetes, renal dysfunction), malnutrition, and performance status. Disease-related factors encompass underlying malignancy type, disease stage, and bone marrow involvement. Treatment-related risks are determined by regimen intensity, degree and duration of neutropenia, use of immunosuppressive agents, central line placement, and exposure to hospital environments. Prolonged neutropenia (>7 days), profound lymphopenia, and high-dose corticosteroid use are particularly predictive of serious infections. Genetic predispositions and prior infection history may also modulate individual risk.

Clinical Features

Infection in immunocompromised cancer patients often presents atypically. Classic signs such as fever may be blunted or absent, particularly with profound neutropenia or corticosteroid use. Localizing symptoms may be subtle or masked. Common infectious syndromes include febrile neutropenia, pneumonia, bloodstream infections, and mucositis-associated sepsis. Opportunistic infections (e.g., Pneumocystis jirovecii, invasive fungal infections, cytomegalovirus, herpesviruses) are more frequent with profound or prolonged immunosuppression. Reactivation of latent infections, such as hepatitis B, tuberculosis, or herpes zoster, is a growing concern with the use of certain targeted and immunomodulatory therapies.

Diagnosis

Prompt identification of infection in cancer patients is paramount. Diagnostic evaluation includes a thorough history and physical examination, with emphasis on recent therapies, immune status, and exposure history. Laboratory assessment should include complete blood count with differential, inflammatory markers, and cultures from blood and other suspected sites. Imaging (e.g., chest radiography, CT) is often required, especially for pulmonary or deep-seated infections. Non-culture based diagnostics, such as PCR for viral or fungal pathogens and galactomannan or beta-D-glucan assays, are valuable in high-risk patients. Risk stratification tools (e.g., MASCC, CISNE) may aid in guiding management, especially for febrile neutropenia.

Treatment & Management

Management of infection risk in cancer patients encompasses both prophylactic and therapeutic strategies. Empiric broad-spectrum antibiotics are the standard of care for febrile neutropenia, with early escalation or de-escalation based on clinical response and microbiological data. Antifungal and antiviral prophylaxis is indicated for select high-risk populations, such as allogeneic HSCT recipients or those receiving intensive lymphodepleting regimens. Colony-stimulating factors (G-CSF, GM-CSF) may be used to shorten neutropenia duration in high-risk settings. Infection control measures, including hand hygiene, environmental precautions, and central line care, are critical. Vaccination (e.g., influenza, pneumococcus) should be optimized where feasible. Multidisciplinary collaboration, including infectious disease consultation, enhances outcomes.

Recent Advances / Emerging Therapies

Recent advances in infection prevention include risk-adapted antimicrobial prophylaxis and the development of novel antifungal and antiviral agents with improved efficacy and safety profiles. The use of granulocyte transfusions and adoptive T-cell therapies is being explored in refractory or high-risk cases. Microbiome modulation, via probiotics or fecal microbiota transplantation, represents an emerging area of research aimed at reducing infection incidence and severity. Biomarker-guided strategies for early infection detection and personalized prophylaxis are also under investigation. Ongoing studies are evaluating the impact of newer immunotherapies and targeted agents on immune function and infection patterns, with the goal of refining risk assessment and mitigation strategies.

Guideline Recommendations

Contemporary guidelines from organizations such as the Infectious Diseases Society of America (IDSA), American Society of Clinical Oncology (ASCO), and European Society for Medical Oncology (ESMO) provide evidence-based recommendations for infection management in cancer patients. Risk stratification is emphasized to guide the use of antibacterial, antifungal, and antiviral prophylaxis. Prompt initiation of empiric therapy for febrile neutropenia, regular vaccination, and strict infection control are standard practices. Preemptive screening for latent infections (e.g., hepatitis B, tuberculosis) before initiating immunosuppressive therapies is advised. Individualization of prophylaxis and therapy based on patient-specific risk factors is strongly recommended.

Conclusion

Treatment-related immune dysfunction remains a formidable challenge in the management of cancer patients, significantly elevating infection risk and impacting clinical outcomes. A nuanced understanding of the mechanisms, risk factors, and clinical manifestations of immunosuppression is essential for clinicians to effectively prevent, diagnose, and manage infectious complications. Advances in prophylactic strategies, diagnostics, and emerging therapies offer promise for reducing infection burden, but require ongoing vigilance and individualized care. Adherence to contemporary guidelines and incorporation of recent evidence will continue to optimize infectious risk mitigation in the oncologic setting.